Inside informationEnglish
Press Release: Sanofi’s Tzield approved in the US as the first disease-modifying therapy for patients recently diagnosed with stage 3 type 1 diabetes
The file is served by the AMF. We do not host a copy.
Document type
- Issuer
- Sanofi
- Filed
- 13/06/2026, 00:09
- Document type
- Inside information
- AMF sub-type
- Informations privilégiées
- Language
- English
- AMF reference
- 117483_20260612